Dr Agarwals Health Care Ltd (AGARWALEYE) Q1 FY27 Results Analysis: PAT Surges 50.5%, Facility Additions Ahead of Schedule
Dr Agarwals Health Care Ltd reported Q1 FY27 numbers with revenue of Rs. 614.02 Cr (+26.00% YoY) and PAT growth of +44.60% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 04, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 614.02 Cr (+26.00% YoY) |
| PAT (Q1) | Rs. 55.02 Cr (+44.60% YoY) |
| EBITDA margin | 28.50% (+30 bps YoY) |
| EPS (Q1) | Rs. 1.43 (+50.50% YoY) |
| Market cap | Rs. 15,630.69 Cr |
| CMP | Rs. 493.50 |
Quarter Snapshot
Revenue grew 26% YoY, beating management's ~21% guidance, and PAT-to-owners surged 50.5% YoY. The company added 18 new facilities in Q1, ahead of schedule, while maintaining stable EBITDA margins. Strong mature-facility growth and debt reduction from IPO proceeds support a positive outlook.
Key Investment Insights
Key Positives
- Revenue grew 26.0% YoY to Rs.614.02 Cr, exceeding management's ~21% growth guidance
- PAT attributable to owners grew 50.5% YoY to Rs.45.23 Cr
- Added 18 new facilities in Q1, including a record 16 surgical facilities, ahead of the FY27 target run-rate
- EBITDA margin remained stable at 28.5% (Total Income basis) despite aggressive greenfield expansion
- Surgery volumes grew 15.5% YoY to 91,082 procedures, with favorable surgical mix shift toward higher-ASP procedures
- Mature Facilities revenue grew 37.1% YoY to Rs.485 Cr, indicating strong same-store performance
- Finance costs declined 5.4% YoY due to debt repayment from IPO proceeds
Risk Factors
- Depreciation expense rose 24.4% YoY to Rs.78.31 Cr, reflecting the heavy capex of prior years, which will continue to weigh on net profit
- Other income fell 52.1% YoY to Rs.6.41 Cr as IPO proceeds were deployed, reducing interest income
- Standalone EBITDA margin compressed 60 bps to 25.9% (vs 26.5% in Q1FY26), indicating margin pressure at the standalone level
- GST show cause notice of Rs.20.50 Cr received, though management does not expect financial impact
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.